Physician profile
Luke S Austin
NPI 1629195532
$2,947,448.37
in general payments reported to CMS, 2019-2025
14 companies · $887K in 2025
The $887K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $419 · 2021: $583K · 2022: $530K · 2023: $519K · 2024: $396K · 2025: $887K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.7M · Consulting Fee: $134K · Travel and Lodging: $11K · Food and Beverage: $2,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,655,267.51 |
| Consulting Fee | $134,084.10 |
| Travel and Lodging | $10,704.85 |
| Food and Beverage | $2,776.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ignite Orthopedics, LLC | $1,823,837.17 | 2019-2025 | |
| Depuy Synthes Products, INC. | $935,747.38 | 2022-2025 | Inhance, Global, Biolox Delta |
| Medical Device Business Services, INC. | $184,082.62 | 2021-2025 | Global, Biolox Delta, Inhance |
| Arthrex, INC. | $1,363.84 | 2021 | |
| Liberty Surgical INC. | $752.50 | 2020-2021 | |
| Depuy Synthes Sales INC. | $737.07 | 2021-2025 | Inhance, Na, Attune |
| Eclipse Technology Solutions INC. | $246.25 | 2022-2025 | |
| Stryker Corporation | $173.85 | 2019-2024 | Inbone |
| Catalyst Orthoscience | $167.85 | 2019 | |
| Exactech, INC. | $135.84 | 2021 | |
| Arthrosurface Incorporated | $129.24 | 2019 | |
| Smith+Nephew, INC. | $46.44 | 2021-2024 | Stravix Mesh |
| Horizon Therapeutics Plc | $28.32 | 2020-2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,909,050.68 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.